• Je něco špatně v tomto záznamu ?

Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS

D. Horakova, P. Rockova, J. Jircikova, T. Dolezal, M. Vachova, P. Hradilek, M. Valis, J. Sucha, A. Martinkova, R. Ampapa, M. Grunermelova, I. Stetkarova, P. Stourac, J. Mares, M. Dufek, E. Kmetova, J. Adamkova, T. Hrnciarova,

. 2019 ; 35 (-) : 196-202. [pub] 20190803

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20023652

BACKGROUND: Proper management of multiple sclerosis (MS) requires feedback from clinical practice via registries. OBJECTIVE: To introduce the Czech national multiple sclerosis registry, ReMuS, and explore the availability and use of disease-modifying drugs (DMD). METHODS: The analysis focused on patients who started their first DMD, either with first-line or second-line medication and was based on reimbursement criteria set by Czech regulators. Baseline information was used to predict relapses after DMD initiation and to compare patients that started DMD in different years. RESULTS: A total of 3,328 patients started DMD treatment for MS between 2013 and 2016; 3,203 on first-line and 125 on second-line medication. The proportion of patients starting on second-line drugs increased from 1.8% in 2013 to 4.7% in 2016. The occurrence of a relapse within one year of DMD initiation was significantly related to (1) the Expanded Disability Status Scale (EDSS) score immediately prior to starting DMD and (2) the number of previous relapses. Both parameters were significantly lower in patients starting in later years of the explored interval. CONCLUSION: Data from the ReMuS registry highlights improvements made in the management of MS in the Czech Republic. However, a relatively low percentage of patients started treatment using second-line drugs, in contrast to trends in other countries.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023652
003      
CZ-PrNML
005      
20201214130726.0
007      
ta
008      
201125s2019 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.msard.2019.08.003 $2 doi
035    __
$a (PubMed)31400559
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Horakova, D $u Dpt. of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czechia. Electronic address: dana.horakova@vfn.cz.
245    10
$a Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS / $c D. Horakova, P. Rockova, J. Jircikova, T. Dolezal, M. Vachova, P. Hradilek, M. Valis, J. Sucha, A. Martinkova, R. Ampapa, M. Grunermelova, I. Stetkarova, P. Stourac, J. Mares, M. Dufek, E. Kmetova, J. Adamkova, T. Hrnciarova,
520    9_
$a BACKGROUND: Proper management of multiple sclerosis (MS) requires feedback from clinical practice via registries. OBJECTIVE: To introduce the Czech national multiple sclerosis registry, ReMuS, and explore the availability and use of disease-modifying drugs (DMD). METHODS: The analysis focused on patients who started their first DMD, either with first-line or second-line medication and was based on reimbursement criteria set by Czech regulators. Baseline information was used to predict relapses after DMD initiation and to compare patients that started DMD in different years. RESULTS: A total of 3,328 patients started DMD treatment for MS between 2013 and 2016; 3,203 on first-line and 125 on second-line medication. The proportion of patients starting on second-line drugs increased from 1.8% in 2013 to 4.7% in 2016. The occurrence of a relapse within one year of DMD initiation was significantly related to (1) the Expanded Disability Status Scale (EDSS) score immediately prior to starting DMD and (2) the number of previous relapses. Both parameters were significantly lower in patients starting in later years of the explored interval. CONCLUSION: Data from the ReMuS registry highlights improvements made in the management of MS in the Czech Republic. However, a relatively low percentage of patients started treatment using second-line drugs, in contrast to trends in other countries.
650    _2
$a dospělí $7 D000328
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunologické faktory $x terapeutické užití $7 D007155
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a roztroušená skleróza $x farmakoterapie $7 D009103
650    _2
$a recidiva $7 D012008
650    _2
$a registrace $7 D012042
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
700    1_
$a Rockova, P $u Dpt. of Neurology, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czechia.
700    1_
$a Jircikova, J $u Value Outcomes s.r.o., Prague, Czechia.
700    1_
$a Dolezal, T $u Value Outcomes s.r.o., Prague, Czechia; Dpt. of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czechia.
700    1_
$a Vachova, M $u Dpt of Neurology, KZ a.s., Hospital Teplice, Teplice, Czechia.
700    1_
$a Hradilek, P $u Clinic of Neurology, University Hospital Ostrava, Ostrava, Czechia.
700    1_
$a Valis, M $u Dpt. of Neurology, Charles University in Prague, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czechia.
700    1_
$a Sucha, J $u Dpt. of Neurology, Charles University in Prague, Faculty of Medicine in Pilsen and University Hospital Pilsen, Pilsen, Czechia.
700    1_
$a Martinkova, A $u Neurology Clinic, Pardubice Regional Hospital and Faculty of Health Studies, University of Pardubice, Pardubice, Czechia.
700    1_
$a Ampapa, R $u Dpt. of Neurology, Hospital of Jihlava, Jihlava, Czechia.
700    1_
$a Grunermelova, M $u Dpt. of Neurology, Thomayer Hospital, Prague, Czechia.
700    1_
$a Stetkarova, I $u Charles University in Prague, Third Faculty of Medicine, Charles University and Hospital Kralovske Vinohrady, Prague, Czechia.
700    1_
$a Stourac, P $u Dpt. of Neurology, University Hospital and Masaryk University, Brno, Czechia.
700    1_
$a Mares, J $u Dpt. of Neurology, Faculty of Medicine, Palacky University and University Hospital Olomouc, Olomouc, Czechia.
700    1_
$a Dufek, M $u First Dpt. of Neurology, Masaryk University, St. Anne's University Hospital, Brno, Czechia.
700    1_
$a Kmetova, E $u Dpt. of Neurology, Tomas Bata Regional Hospital, Zlin, Czechia.
700    1_
$a Adamkova, J $u Dpt. od Neurology, Hospital Ceske Budejovice, Ceske Budejovice, Czechia.
700    1_
$a Hrnciarova, T $u Dpt. of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czechia; Value Outcomes s.r.o., Prague, Czechia.
773    0_
$w MED00188780 $t Multiple sclerosis and related disorders $x 2211-0356 $g Roč. 35, č. - (2019), s. 196-202
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31400559 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214130725 $b ABA008
999    __
$a ok $b bmc $g 1595971 $s 1114328
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 35 $c - $d 196-202 $e 20190803 $i 2211-0356 $m Multiple sclerosis and related disorders $n Mult Scler Relat Disord $x MED00188780
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace